カテゴリ： GlobalData, フランス, 企業調査

Advanced Accelerator Applications SA (AAAP)-医療機器分野：企業M&A・提携分析

◆英語タイトル：Advanced Accelerator Applications SA (AAAP) - Medical Equipment - Deals and Alliances Profile
◆商品コード：DATA8011378
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月22日
◆ページ数：57
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：フランス
◆産業分野：医療機器
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Advanced Accelerator Applications SA (AAA) is a healthcare products provider that offers molecular nuclear medicine and diagnostic and therapeutic products. The company’s lead product candidate comprises Lutathera, a lutetium-177 somatostatin analogue peptide that is used for the treatment of midgut neuroendocrine tumors. It provides positron emission tomography and single photon emission computed tomography products. AAA caters to diagnosis in clinical cardiology, oncology, neurology, and infectious and inflammatory diseases. It operates in France, Italy, the UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, the US, and Canada, among others. AAA is headquartered in Saint-Genis-Pouilly, France.

Advanced Accelerator Applications SA (AAAP) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Advanced Accelerator Applications SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Advanced Accelerator Applications SA, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Advanced Accelerator Applications SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Advanced Accelerator Applications SA, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Advanced Accelerator Applications SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Advanced Accelerator Applications SA, Medical Equipment, Deal Details 12
Asset Purchase 12
Advanced Accelerator Applications to Acquire Two Production Sites in Germany 12
Advanced Accelerator Applications Acquires Positron Emission Tomography from GE Healthcare 13
Venture Financing 14
Advanced Accelerator Applications Raises US$56 Million In Venture Financing 14
Advanced Accelerator Raises US$6 Million In First Tranche Of Venture Financing 15
Advanced Accelerator Secures US$57 Million In Venture Financing 16
Partnerships 17
Advanced Accelerator Applications Enters into Distribution Agreement with Blue Earth Diagnostics 17
Itel Telecomunicazioni Enters into Agreement with Advanced Accelerator Applications 18
Eveon Enters into Agreement with Advanced Accelerator Applications 19
Advanced Accelerator Applications Enters Into Co-Development Agreement With University of Warsaw 20
Equity Offering 21
Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 21
Advanced Accelerator Applications to Raise up to USD80 Million in IPO 23
Acquisition 25
Novartis to Acquire Advanced Accelerator Applications for USD3.9 Billion 25
Advanced Accelerator Applications Acquires Imaging Equipment 27
Advanced Accelerator Applications Acquires Barnatron 28
Advanced Accelerator Applications Acquires Catalana De Dispensacion 29
Ion Beam Applications Acquires 25% Stake In PET Net 30
Advanced Accelerator Applications SA – Key Competitors 31
Advanced Accelerator Applications SA – Key Employees 32
Advanced Accelerator Applications SA – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 35
Financial Announcements 35
Nov 17, 2017: Advanced Accelerator Applications Reports 39% Sales Growth for Third Quarter 2017 35
May 31, 2017: Advanced Accelerator Applications Reports 21% Sales Growth for First Quarter 2017 36
Mar 23, 2017: Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT Launch Success 38
Nov 28, 2016: Advanced Accelerator Applications Reports 15.4% Sales Growth in the Third Quarter of 2016 40
Aug 31, 2016: Advanced Accelerator Applications Reports 24.4% Sales Growth in the Second Quarter of 2016 41
May 31, 2016: Advanced Accelerator Applications Reports 29.6% Sales Growth in the First Quarter of 2016 42
Apr 29, 2016: Advanced Accelerator Applications reports 26.8% sales growth in 2015 and continues to show significant clinical progress across both therapeutic and diagnostic platforms 44
Corporate Communications 45
May 25, 2017: Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors 45
May 26, 2016: Advanced Accelerator Applications Appoints Francois Nader, M.D., to Board of Directors 46
Product News 47
Dec 08, 2016: Advanced Accelerator Applications Announces CMS Pass-Through Reimbursement Code for its First FDA Approved Drug NETSPOT 47
Nov 02, 2016: Advanced Accelerator Applications Announces Swiss Marketing Authorization for Two PET Diagnostic Products 48
Sep 22, 2016: EMA Recommends Granting a Marketing Authorisation for Edotreotide 49
Aug 03, 2016: Advanced Accelerator Applications Announces First Administration of NETSPOT™ at Holy Name Medical Center 50
Jun 02, 2016: Advanced Accelerator Applications Announces FDA Approval of NETSPOT (Somakit-TATE), a Kit for the Preparation of Gallium Ga 68 Dotatate for Neuroendocrine Tumor Detection 51
Other Significant Developments 52
Jan 09, 2017: Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera NDA 52
Jun 10, 2016: Advanced Accelerator Applications Expands U.S. NETSPOT Supply Chain with Two Additional Radiopharmacy Networks 54
Jun 09, 2016: Cardinal Health to Prepare NETSPOT Doses for Advanced Accelerator Applications 55
Jan 26, 2016: Zevacor to Produce SomaKit-TATE Doses for AAA 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Advanced Accelerator Applications SA, Medical Equipment, Key Facts, 2016 2
Advanced Accelerator Applications SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Advanced Accelerator Applications SA, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Advanced Accelerator Applications SA, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Advanced Accelerator Applications SA, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Advanced Accelerator Applications SA, Deals By Market, 2011 to YTD 2017 9
Advanced Accelerator Applications SA, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Advanced Accelerator Applications to Acquire Two Production Sites in Germany 12
Advanced Accelerator Applications Acquires Positron Emission Tomography from GE Healthcare 13
Advanced Accelerator Applications Raises US$56 Million In Venture Financing 14
Advanced Accelerator Raises US$6 Million In First Tranche Of Venture Financing 15
Advanced Accelerator Secures US$57 Million In Venture Financing 16
Advanced Accelerator Applications Enters into Distribution Agreement with Blue Earth Diagnostics 17
Itel Telecomunicazioni Enters into Agreement with Advanced Accelerator Applications 18
Eveon Enters into Agreement with Advanced Accelerator Applications 19
Advanced Accelerator Applications Enters Into Co-Development Agreement With University of Warsaw 20
Advanced Accelerator Applications Prices Public Offering of American Depositary Shares for USD172.5 Million 21
Advanced Accelerator Applications to Raise up to USD80 Million in IPO 23
Novartis to Acquire Advanced Accelerator Applications for USD3.9 Billion 25
Advanced Accelerator Applications Acquires Imaging Equipment 27
Advanced Accelerator Applications Acquires Barnatron 28
Advanced Accelerator Applications Acquires Catalana De Dispensacion 29
Ion Beam Applications Acquires 25% Stake In PET Net 30
Advanced Accelerator Applications SA, Key Competitors 31
Advanced Accelerator Applications SA, Key Employees 32
Advanced Accelerator Applications SA, Subsidiaries 33

★海外企業調査レポート[Advanced Accelerator Applications SA (AAAP)-医療機器分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • AbbVie Inc (ABBV)：製薬・医療：M&Aディール及び事業提携情報
    Summary AbbVie Inc (AbbVie) is a research-based biopharmaceutical company that develops, manufactures and commercializes advanced therapies for treating complex and serious diseases. It provides pharmaceutical drugs to treat conditions in rheumatology, gastroenterology, dermatology, oncology, virolo …
  • Gulf Cement Company PSC：企業の戦略・SWOT・財務情報
    Gulf Cement Company PSC - Strategy, SWOT and Corporate Finance Report Summary Gulf Cement Company PSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Nielsen Holdings plc (NLSN)：企業の財務・戦略的SWOT分析
    Nielsen Holdings plc (NLSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Qantas Airways Ltd (QAN)：企業の財務・戦略的SWOT分析
    Qantas Airways Ltd (QAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • China International Water & Electric Corp：企業の戦略的SWOT分析
    China International Water & Electric Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Advanced Digital Broadcast SA：企業の戦略的SWOT分析
    Advanced Digital Broadcast SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • TransCanada Corp (TRP)：石油・ガス：M&Aディール及び事業提携情報
    Summary TransCanada Corp (TransCanada) is an energy infrastructure company. It develops and operates energy infrastructure, such as natural gas and liquids pipelines, power generation and gas storage facilities. The company also provides gas storage related services and operates in the regulated and …
  • SeraCare Life Sciences, Inc.：医療機器：M&Aディール及び事業提携情報
    Summary SeraCare Life Sciences, Inc. (SeraCare) carries out the discovery, development, manufacture and supply of disease-state specimens and tissues for research and development, processed biological materials, immunoassay reagents and quality control products and technologies. Its major products i …
  • Wirecard AG：企業の戦略・SWOT・財務分析
    Wirecard AG - Strategy, SWOT and Corporate Finance Report Summary Wirecard AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Balfour Beatty plc：企業の戦略・SWOT・財務情報
    Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report Summary Balfour Beatty plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Fortune Electric Co Ltd (1519)：企業の財務・戦略的SWOT分析
    Summary Fortune Electric Co Ltd (Fortune Electric) is a power company that manufactures and markets transformers and accessories. The company's products include distribution transformers, power transformers, cast resin transformers and amorphous metal alloy core transformers, among others. It offers …
  • Linde AG (LIN)-医療機器分野：企業M&A・提携分析
    Summary Linde AG (Linde) is a provider of industrial gases and engineering services. The company specializes in the planning, procurement, construction and operation of gas production and processing plants. Linde offers a wide range of compressed and liquefied gases, and chemicals, and offers facili …
  • Aprecia Pharmaceuticals Company：製薬・医療：M&Aディール及び事業提携情報
    Summary Aprecia Pharmaceuticals Company (Aprecia) is a drug delivery technology platform company that develops pharmaceutical drug products. The company offers Zipdose technology, a delivery platform that serves as the foundation of orodispersible formulations of prescribed high-dose medications. It …
  • CJ ENM Co Ltd (035760)：企業の財務・戦略的SWOT分析
    CJ ENM Co Ltd (035760) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Delta Apparel, Inc. (DLA)：企業の財務・戦略的SWOT分析
    Delta Apparel, Inc. (DLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • HeidelbergCement AG：戦略・SWOT・企業財務分析
    HeidelbergCement AG - Strategy, SWOT and Corporate Finance Report Summary HeidelbergCement AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Presence Health：企業の戦略的SWOT分析
    Presence Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Dicerna Pharmaceuticals Inc (DRNA)：企業の財務・戦略的SWOT分析
    Summary Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platf …
  • aTyr Pharma Inc (LIFE)：企業の財務・戦略的SWOT分析
    Summary ATyr Pharma Inc (ATyr Pharma) is a clinical-stage biotechnology company engaged in the discovery and clinical development of medicines for the treatment of cancer and lung diseases. Its ATYR1923 is a clinical-stage product candidate, based on the resokine pathway, which binds to the neuropil …
  • Bill Peach Group Limited：企業の戦略・SWOT・財務情報
    Bill Peach Group Limited - Strategy, SWOT and Corporate Finance Report Summary Bill Peach Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆